A 48-year-old woman with CKD Stage 4 (eGFR 18 mL/min/1.73m²) and hypertension is evaluated for bone-mineral metabolism disturbances. Which investigation is most appropriate to assess secondary hyperparathyroidism and guide management?

## Investigation of Choice for CKD Mineral Bone Disorder (CKD-MBD) ### Clinical Context This patient with Stage 4 CKD (eGFR 18) is at high risk for secondary hyperparathyroidism and CKD-mineral bone disorder (CKD-MBD). The question asks for the **most comprehensive and guideline-recommended investigation** to assess bone-mineral metabolism. ### Why Serum iPTH, Calcium, Phosphate, and 25-OH Vitamin D is the Answer **Key Point:** The **KDIGO (Kidney Disease: Improving Global Outcomes) guidelines** recommend assessment of the triad of: 1. **Parathyroid hormone (PTH)** — marker of parathyroid activity 2. **Serum calcium and phosphate** — mineral metabolism parameters 3. **25-hydroxyvitamin D** — vitamin D status and substrate for renal activation **High-Yield:** This 4-parameter panel forms the **diagnostic foundation for CKD-MBD** and guides therapeutic decisions: - **iPTH elevation** (>65 pg/mL in Stage 4 CKD) indicates secondary hyperparathyroidism - **Hyperphosphatemia** (>4.5 mg/dL) worsens PTH suppression resistance - **Hypocalcemia** stimulates PTH secretion; corrected calcium guides calcitriol dosing - **Low 25-OH vitamin D** (<30 ng/mL) impairs PTH suppression and bone health ### Pathophysiology of Secondary Hyperparathyroidism in CKD ```mermaid flowchart TD A[Declining GFR]:::outcome --> B[↓ Phosphate excretion]:::outcome A --> C[↓ Calcitriol production]:::outcome B --> D[Hyperphosphatemia]:::outcome C --> E[Hypocalcemia]:::outcome D --> F[↑ FGF23]:::outcome E --> F F --> G[↑ PTH secretion]:::outcome G --> H[Secondary hyperparathyroidism]:::urgent H --> I[Parathyroid hyperplasia]:::outcome ``` ### Recommended Testing Schedule | CKD Stage | Frequency | Parameters | |---|---|---| | **Stage 3a–3b** | Annually | iPTH, Ca, P, 25-OH Vit D | | **Stage 4** | Every 3–6 months | iPTH, Ca, P, 25-OH Vit D | | **Stage 5** | Every 1–3 months | iPTH, Ca, P, 25-OH Vit D | **Clinical Pearl:** iPTH levels should be maintained within 2–9 times the upper limit of normal for the assay (typically 150–300 pg/mL in Stage 4) to prevent both hyperparathyroidism and adynamic bone disease. ### Why Alkaline Phosphatase Alone is Insufficient **Warning:** Serum alkaline phosphatase (total or bone-specific) is a **marker of bone turnover**, not a diagnostic test for secondary hyperparathyroidism. It may be normal or elevated depending on bone histology and does not assess mineral metabolism directly. It cannot replace PTH, calcium, and phosphate measurement. [cite:KDIGO 2017 CKD-MBD Guidelines; Harrison 21e Ch 279]